Clarithromycin

Generic Name: Clarithromycin

Brand Names: Biaxin, Biaxin Bid, Omeclamox, Prevpac, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₃₈H_₆₉NO_₁₃

CAS Number: 81103-11-9

Unique Ingredient Identifier: H1250JIK0A

Background: Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bacteri...

Indication: An alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinu...

Associated Conditions: Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Acute maxillary sinusitis, Bacterial Infections, Bartonellosis, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Helicobacter Pylori Infection, Infective Endocarditis (IE), Lyme Disease, Mycobacterial Infections, Otitis Media (OM), Pertussis, Streptococcal Pharyngitis, Tonsillitis streptococcal, Uncomplicated skin and subcutaneous tissue bacterial infections

Associated Therapies: -

Clinical Trials

The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori

Not Applicable

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Vonoprazan
Drug: Esomeprazole
Drug: Amoxicillin
Drug: Bismuth potassium citrate
Drug: Clarithromycin

First Posted Date: 2022-01-12

Last Posted Date: 2022-03-22

Lead Sponsor: Huazhong University of Science and Technology

Target Recruit Count: 672

Registration Number: NCT05189444

Locations: 🇨🇳
Tongji Hospital, Tongji Medical College, HUST, Wuhan, Hubei, China

A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects

Phase 1

Completed

Conditions: Drug Drug Interaction

Interventions: Drug: Midazolam
Drug: ATI-2173
Drug: Clarithromycin

First Posted Date: 2021-11-30

Last Posted Date: 2022-02-04

Lead Sponsor: Antios Therapeutics, Inc

Target Recruit Count: 36

Registration Number: NCT05137600

Locations: 🇨🇦
Altasciences, Montréal, Quebec, Canada

Helicobacter Pylori Eradication and Follow-up

Phase 4

Recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Rabeprazole
Drug: Bismuth potassium citrate
Drug: Metronidazole
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Levofloxacin
Drug: Doxycycline
Drug: Tetracycline

First Posted Date: 2021-09-30

Last Posted Date: 2021-09-30

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 4447

Registration Number: NCT05061732

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

Phase 4

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Amoxicillin
Drug: Clarithromycin
Drug: Tetracycline
Drug: Metronidazole
Drug: Bismuth Potassium Citrate
Drug: Colloidal Bismuth Pectin
Drug: Vonoprazan fumarate

First Posted Date: 2021-09-20

Last Posted Date: 2023-07-19

Lead Sponsor: Shandong University

Target Recruit Count: 1300

Registration Number: NCT05049902

Locations: 🇨🇳
Maternity and Child Care Health Center of Dezhou, Dezhou, Shandong, China
🇨🇳
Heze Municipal 3rd people's hospital, Heze, Shandong, China
🇨🇳
Qilu hosipital, Jinan, Shandong, China

and more 3 locations

Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients

Phase 4

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Rabeprazole
Drug: Bismuth potassium citrate
Drug: Clarithromycin
Drug: Metronidazole
Drug: Levofloxacin

First Posted Date: 2021-08-26

Last Posted Date: 2021-09-14

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 504

Registration Number: NCT05023577

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication

Phase 4

Completed

Conditions: Helicobacter Pylori Infection
Chronic Gastritis

Interventions: Drug: Berberine
Drug: Vonoprazan
Drug: Rabeprazole
Drug: Amoxicillin
Drug: Bismuth
Drug: Clarithromycin

First Posted Date: 2021-08-20

Last Posted Date: 2023-01-31

Lead Sponsor: Xijing Hospital of Digestive Diseases

Target Recruit Count: 300

Registration Number: NCT05014334

Locations: 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days

Phase 4

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Amoxicillin
Drug: Clarithromycin
Drug: Tetracycline
Drug: Metronidazole
Drug: Bismuth Potassium Citrate
Drug: Colloidal Bismuth Pectin
Drug: Vonoprazan fumarate

First Posted Date: 2021-05-25

Last Posted Date: 2021-05-25

Lead Sponsor: Shandong University

Target Recruit Count: 1300

Registration Number: NCT04901117

Locations: 🇨🇳
Qilu hosipital, Jinan, Shandong, China

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

Phase 2

Terminated

Conditions: Myeloma
Myeloma Multiple
Refractory Multiple Myeloma

Interventions: Drug: Selinexor
Drug: Clarithromycin
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2021-04-13

Last Posted Date: 2023-10-25

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 4

Registration Number: NCT04843579

Locations: 🇺🇸
Weill Cornell Medicine - Multiple Myeloma Center, New York, New York, United States
🇺🇸
NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States